FMC WKN: 871138 ISIN: US3024913036 Forum: Aktien Thema: Hauptdiskussion

Das dauert

V- förmige Erholung wär geil

https://investors.fmc.com/news/news-details/2026/FMC-Corporation-reports-second-quarter-2026-results-with-Adjusted-EBITDA-above-high-end-of-guidance-range-and-solid-cash-generation/default.aspx

Zahlen sind da

Das erste Mal seit 2005 unter 10 Dollar. Unglaublich.

Steht es ja jetzt schon fast

Da kann morgen auch die 8,50 € stehen!

FMC price target lowered to $16 from $20 at Mizuho TheFly Jul 14, 2026, 02:06 PM Mizuho lowered the firm’s price target on FMC (FMC) to $16 from $20 and keeps a Neutral rating on the shares. The firm adjusted targets in the chemicals group as part of a Q2 preview. Phosphate “remains in a bind” as higher prices to recover margins are driving demand destruction, the analyst tells investors in a research note. In addition, production is being curtailed due to lack of sulfur availability as well as higher costs, but potash “remains an island of stability,” adds Mizuho.

Habe nix darüber bei google gefunden. Es gab mal ein Gerücht wurde nicht bestätigt.

Ich denke der Kursanstieg ist den geopolitischen Spannungen geschuldet. Nutrien und Mosaic sind heute auch grün.

Gemini Analysis spricht nun plötzlich von einem möglichen Verkauf des gesamten Unternehmens. Handelt es sich dabei um eine neue Entwicklung? In jedem Fall schießt der Aktienkurs in die Höhe.

Moin moin bin nun auch dabei.

3 CEOs Just Spent Millions Buying Their Beaten-Down Stock By Ed Lin March 09, 2025, 3:00 am EDT FMC Chairman and CEO Pierre R. Brondeau paid $1.9 million on March 4 for 54,000 shares of the agricultural-sciences firm, an average price of $35.90 each. He now owns 298,439 FMC shares. FMC shares tumbled in early February after the company provided an outlook that fell short of analyst expectations. “My recent purchase of nearly $2 million in FMC shares reflects my personal confidence in our company’s strategy and future,” Brondeau wrote in an email in response to a request for comment. “The current share price presented what I view as a compelling opportunity to increase my personal investment in a company whose short-term and long-term prospects I firmly believe in.” https://www.barrons.com/articles/ceo-stock-buys-moderna-fmc-akamai-f1373290?mod=mw_quote_news&adobe_mc=MCMID%3D14605416935782053551746103278121613868%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1783674581

FMC Advances Regulatory Submission for Innovative Herbicide Rimisoxafen GuruFocus News 07/08/2026 22:51 On July 08, 2026, FMC has officially submitted its regulatory dossier for rimisoxafen to the U.S. Environmental Protection Agency (EPA), marking a significant milestone as it represents the first such submission worldwide for this novel herbicide ingredient. This filing includes its application on crops such as corn, soybean, sunflower, and select pulse varieties. What's Behind the News? The submission of the regulatory dossier for rimisoxafen is a pivotal development for FMC Corp, as it showcases the company's commitment to innovation in the agricultural sector. Rimisoxafen, developed at FMC's Stine Research Center, is distinguished by its dual mode of action, which targets two separate biochemical pathways in weeds. This innovative approach aims to mitigate the risk of herbicide resistance, a growing concern in modern agriculture. The significance of this submission is amplified by the fact that it is the first of its kind globally, positioning FMC as a leader in herbicide development.

Gemini: Ups, von 17 auf 12 Dollar. Warum, wo doch die Schuldenreduzierung um 1 Milliarde Dollar bereits erreicht wurde?: UBS analysts maintain a Neutral rating on FMC Corporation (NYSE: FMC) with a price target raised to $17.00 (from $14.00). The cautious valuation reflects headwinds from declining crop chemical demand, inventory destocking, and ongoing pressure on earnings, despite the company's aggressive restructuring efforts like selling its India commercial business.Analyst Consensus & TargetUBS Rating: NeutralUBS Price Target: $17.00 (up from $14.00)Consensus Rating: HoldConsensus Average Target: ~$13.00 to $16.52Key Drivers Behind the AnalysisMarket Headwinds: A prolonged downturn in crop protection markets and weak demand volumes have significantly impacted FMC's sales trajectory.Financial Pressures: Consecutive years of subdued EBITDA, elevated debt levels, and the suspension of dividends have weighed heavily on investor sentiment.Restructuring & Debt Reduction: To counter declining cash flows, FMC agreed to sell its India commercial business and set aggressive targets to pay down $1 billion in debt.Strategic Pivot: Shifts toward a direct-to-farm sales model—particularly in complex markets like Brazil—add near-term execution risks to their delivery and cost-reduction plans.